PMID- 11316142
OWN - NLM
STAT- MEDLINE
DCOM- 20010628
LR  - 20151119
IS  - 0002-9270 (Print)
IS  - 0002-9270 (Linking)
VI  - 96
IP  - 4
DP  - 2001 Apr
TI  - Intragastric acidification reduces the occurrence of false-negative urea breath 
      test results in patients taking a proton pump inhibitor.
PG  - 1028-32
AB  - OBJECTIVE: The aim of this study was to investigate whether reducing intragastric 
      pH, at the time of urea ingestion, decreases the likelihood of false-negative 
      (FN) urea breath test (UBT) results in patients taking a proton pump inhibitor 
      (PPI). METHODS: Patients with active Helicobacter pylori infection underwent a 
      baseline 14C-UBT (UBT-1) followed by treatment with lansoprazole 30 mg/day for 14 
      to 16 days. On day 13, patients returned for a repeat standard UBT (UBT-2). 
      Between days 14 to 16, patients underwent a modified UBT (UBT-3), which included 
      consuming 200 ml of 0.1 N citrate solution 30 min before and at the time of 
      14C-urea administration. Breath samples were collected 10 and 15 min after 
      14C-urea ingestion. Mean 14CO2 excretion and the number of FN and equivocal UBT 
      results were compared for the three UBTs. RESULTS: A total of 20 patients 
      completed the study. Lansoprazole caused a significant decrease in mean breath 
      14CO2 excretion (disintegrations per minute) between UBT-1 (2.96 +/- 0.23) and 
      UBT-2 (2.08 +/- 0.52, p < 0.05). Lansoprazole caused six (30%) FN and eight (40%) 
      equivocal UBT-2 results. Mean breath 14CO2 excretion for UBT-3 (677 +/- 514) was 
      greater than for UBT-2 (234 +/- 327, p = 0.001). UBT-3 caused only two (10%) FN 
      and three (15%) equivocal results. The 15-min breath sample caused fewer FN and 
      equivocal results than the 10-min sample for both UBT-2 and UBT-3. CONCLUSIONS: 
      Giving citrate before and at the time of 14C-urea administration increases mean 
      breath 14CO2 excretion and decreases FN and equivocal UBT results in patients 
      taking a PPI. These observations suggest that it may be possible to design a UBT 
      protocol that will remain accurate in the face of PPI therapy.
FAU - Chey, W D
AU  - Chey WD
AD  - University of Michigan Health System, Ann Arbor, USA.
FAU - Chathadi, K V
AU  - Chathadi KV
FAU - Montague, J
AU  - Montague J
FAU - Ahmed, F
AU  - Ahmed F
FAU - Murthy, U
AU  - Murthy U
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Gastroenterol
JT  - The American journal of gastroenterology
JID - 0421030
RN  - 0 (2-Pyridinylmethylsulfinylbenzimidazoles)
RN  - 0 (Proton Pump Inhibitors)
RN  - 0K5C5T2QPG (Lansoprazole)
RN  - 8W8T17847W (Urea)
RN  - KG60484QX9 (Omeprazole)
SB  - IM
CIN - Am J Gastroenterol. 2001 Oct;96(10):3037-9. PMID: 11693351
MH  - 2-Pyridinylmethylsulfinylbenzimidazoles
MH  - *Breath Tests
MH  - False Negative Reactions
MH  - Female
MH  - Gastric Acidity Determination
MH  - Helicobacter Infections/drug therapy/metabolism
MH  - Helicobacter pylori
MH  - Humans
MH  - Hydrogen-Ion Concentration
MH  - Lansoprazole
MH  - Male
MH  - Middle Aged
MH  - Omeprazole/*analogs & derivatives/*pharmacology/therapeutic use
MH  - *Proton Pump Inhibitors
MH  - Sensitivity and Specificity
MH  - Urea/*metabolism
EDAT- 2001/04/24 10:00
MHDA- 2001/06/29 10:01
CRDT- 2001/04/24 10:00
PHST- 2001/04/24 10:00 [pubmed]
PHST- 2001/06/29 10:01 [medline]
PHST- 2001/04/24 10:00 [entrez]
AID - S0002-9270(01)02250-X [pii]
AID - 10.1111/j.1572-0241.2001.03687.x [doi]
PST - ppublish
SO  - Am J Gastroenterol. 2001 Apr;96(4):1028-32. doi: 
      10.1111/j.1572-0241.2001.03687.x.